“Structural Biology is changing the way we design drugs”

10/12/2015 - 5 minutes

proteros structural biology psdi

Structural biology, the study of the structure of biological macromolecules, is becoming a real asset in the drug development process. The PSDI meeting is THE not-to-be-missed event for the experts in this field. Labiotech.eu gives you a glimpse of the last trends discussed during this conference thanks to our exclusive interview with Dr Peter Reinemer, COO of Proteros.

For those who missed it, we have already presented a detailed profile of Proteros in a previous article. This German company is a leader of the Structural Biology field, providing its high-level services to other Pharma or Biotech companies in need of such specific knowledge. Recently the company also started developing its own portfolio of drugs including a promising candidate that could play a role in CNS-related diseases, for example.

The PSDI is a once-a-year event, famous in the field for being the place where the experts meet and exchange their latest discoveries. This year was the first time a Biotech company like Proteros organized the PSDI meeting.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member